2023
DOI: 10.3390/ijms241411434
|View full text |Cite
|
Sign up to set email alerts
|

Friend or Foe? Locoregional Therapies and Immunotherapies in the Current Hepatocellular Treatment Landscape

Abstract: Over the last several decades, a number of new treatment options for patients with hepatocellular carcinoma (HCC) have been developed. While treatment decisions for some patients remain clear cut, a large numbers of patients have multiple treatment options, and it can be hard for multidisciplinary teams to come to unanimous decisions on which treatment strategy or sequence of treatments is best. This article reviews the available data with regard to two treatment strategies, immunotherapies and locoregional th… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
3
1

Relationship

1
3

Authors

Journals

citations
Cited by 4 publications
(1 citation statement)
references
References 110 publications
0
1
0
Order By: Relevance
“…The second of the three articles reviews the development of new treatment options for HCC [ 7 ], the most common primary liver cancer and a leading cause of cancer-related deaths globally. Categorising HCC patients has always been problematic, given the frequent presence of cirrhosis and HCC.…”
mentioning
confidence: 99%
“…The second of the three articles reviews the development of new treatment options for HCC [ 7 ], the most common primary liver cancer and a leading cause of cancer-related deaths globally. Categorising HCC patients has always been problematic, given the frequent presence of cirrhosis and HCC.…”
mentioning
confidence: 99%